0.05
+0(+0.00%)
Currency In USD
| Previous Close | 0.05 |
| Open | 0.05 |
| Day High | 0.05 |
| Day Low | 0.05 |
| 52-Week High | 0.05 |
| 52-Week Low | 0.05 |
| Volume | 260 |
| Average Volume | 30,603.29 |
| Market Cap | 15.46M |
| PE | -0.03 |
| EPS | -1.73 |
| Moving Average 50 Days | 0.08 |
| Moving Average 200 Days | 0.05 |
| Change | 0 |
Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment
GlobeNewswire Inc.
Sep 17, 2025 12:45 PM GMT
Strategic Commercial Supply Agreement Positions Lead Asset CTx-1301 for Launch Pending FDA ApprovalKANSAS CITY, Kan., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision
Cingulate Provides Management Team Update
GlobeNewswire Inc.
Aug 15, 2025 1:00 PM GMT
Jennifer Callahan, Chief Financial Officer, appointed Interim CEO Board member, Jay Roberts appointed Executive Chairman KANSAS CITY, Kan., Aug. 15, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CING) The Board of Directors of Cingulate Inc. (“Cingulate”) ann
Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301
GlobeNewswire Inc.
Aug 06, 2025 12:45 PM GMT
Regulatory filing marks significant milestone for medication designed to provide once-daily, entire active-day symptom control in ADHD patientsKANSAS CITY, Kan., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical c
Data not available